SEC Form 4 · accession 0001127602-18-003872
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin Young
Officer — Chief Operating Officer
Period of report
Jan 31, 2018
Accepted (ET)
Feb 2, 2018 · 9:14 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 31, 2018 | A | 7,110 | $0.00 | A | 17,186 | D | |
| Common Stock | Jan 31, 2018 | F | 2,259 | $83.80 | D | 14,927 | D | |
| Common Stock | Feb 1, 2018 | M | 620 | $0.00 | A | 15,547 | D | |
| Common Stock | Feb 1, 2018 | F | 218 | $83.49 | D | 15,329 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF2,F3 | — | Feb 1, 2018 | M | 620 | D | — | — | Common Stock | 620 | 4,092 | D |
Explanation of responses
- F1Issuance of common stock upon vesting of certain performance share awards on January 31, 2018.
- F2Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
- F3The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.